Lugano, Switzerland, August 8, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its […]

Lugano, Switzerland, June 02, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its […]

New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc. (HTU) and will support clinical work across Helsinn Group’s diversified pipeline of […]

Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record […]

MONTREAL, Quebec and LUGANO, Switzerland – May 12, 2022 – Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare […]

Lugano, Switzerland, May 11, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, is pleased […]

Lugano, Switzerland, and Singapore, 04 May 2022 – Juniper Biologics Pte Ltd , a science-led healthcare company focused on researching, developing and commercializing novel therapies,and […]

Tokyo, Japan, and Lugano, Switzerland March 28, 2022 – Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) and Helsinn Group (hereinafter “Helsinn”), announced today that Taiho has […]

Helsinn gains an exclusive license to commercialize infigratinib in the U.S. Lugano, Switzerland and Palo Alto, CA, March 3, 2022 – Helsinn Group (Helsinn), a […]

Toronto, Ontario and Lugano, Switzerland, February 16, 2022 Verity Pharmaceuticals International Ltd. (“Verity Pharma”), and Helsinn Therapeutics (U.S.), Inc. (“Helsinn”), today announced the signing of […]